Generic medicines hit Novartis profits | Inquirer Business

Generic medicines hit Novartis profits

/ 05:05 PM July 18, 2017

A sign for Novartis International pharmaceutical company is seen on a building in Cambridge, Massachusetts, on March 18, 2017. AFP

Swiss drugmaker Novartis on Tuesday posted a drop in first half profits amid fierce competition for generic medicines and pricing pressures but said it was set to reach annual targets.

January-June net core income dropped 5 percent to $3.6 billion (3.1 billion euros), as overall first half sales dipped one percent to $23.7 billion, despite a six percent rise in volume, the group said.

Article continues after this advertisement

Those volumes were buoyed by two medicines deemed to have strong potential — heart drug Entresto and Cosentyx, a treatment for psoriasis.

FEATURED STORIES

Stiff competition for generic medicine — not least copy cat drugs for its blockbuster cancer drug Gleevec — has eaten away some 3 percent of current profit margins, while price pressures have accounted for another 2 percent.

For the outlook for the year as a whole Novartis reconfirmed its objectives in saying it expected global sales this year to hit similar levels to 2016.

Article continues after this advertisement

In January, the group announced total sales of $48.5 billion for 2016.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Business, Earnings, novartis, pharmaceuticals, Switzerland

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.